Market Intelligence, Clinical Progress, and High-Purity Reagents for Platelet-Related Disorders and Anti-Thrombotic Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GP9 (CD42a) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GP9 (CD42a) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View GP9 Products |
| Gene Delivery | GP9 (CD42a) Promise-ORF / Lentivirus Full-length ORF for stable cell lines and surface expression validation. |
View GP9 Products |
| Benchmark Ab | Anti-GP9 (CD42a) Recombinant Antibody Recombinant positive control for binding and flow cytometry assays. |
View GP9 Products |
| Validator | GP9 (CD42a) siRNA Set For knockdown verification in megakaryocytic cell lines. |
View GP9 Products |
| Related Target A | GP1BA (CD42b) Forms the functional GPIb-IX-V complex with GP9; critical for vWF binding. |
View GP1BA Products |
| Related Target B | GP1BB (CD42c) Key structural partner in the GPIb-IX complex, co-dependent with GP9 for surface transport. |
View GP1BB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational antibody screening | Lentivirus-based stable cell line construction ensuring native GPIb-IX complex assembly |
| Receptor complex stoichiometry validation | High-purity monomers and co-expression tools with verified protein sequences |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included |
| False Positives | Validated siRNA sets included for target specificity verification |
Live GP9 (CD42a) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the platelet GPIb-IX-V complex, specifically the GP9 (CD42a) subunit, represents a highly specialized frontier in hematology and cardiovascular medicine. GP9 is essential for the stable surface expression and structural integrity of the GPIb-IX complex, which mediates platelet adhesion to damaged vascular endothelium via Von Willebrand Factor (vWF) interactions under high shear stress.
The race for GP9 (CD42a) therapeutics is intensifying, with major players shifting focus from traditional systemic anticoagulants to targeted anti-thrombotic mAbs and diagnostic tools for Bernard-Soulier syndrome. As first-generation anti-platelet therapies reach the clinic, the next wave of R&D is targeting highly selective modulation of the GPIb-IX complex to prevent arterial thrombosis while minimizing the risk of severe bleeding complications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Academic Medical Centers, Biotech Startups | Thrombosis Prevention, Bernard-Soulier Diagnostics | Conformational Binding Assays (Need HEK293-expressed ECD-Fc) |
| Gene Therapy | Orphan Drug Developers | Bernard-Soulier Syndrome (GP9 Deficiency) | Stable Surface Expression Verification (Need Lentivirus for Stable Cell Lines) |
| Small Molecule Inhibitors | Pharmaceutical Research Institutes | Arterial Thrombosis, Stroke Prevention | In vitro binding inhibition assays (Need High-Purity Recombinant Antigens) |